SEQUENCE LISTING

<110> Clinton, Gail M.
      Evans, Adam
      Henner, William D.

<120> HER-2 BINDING ANTAGONISTS

<130> 49321-16

<140> US 09/506,079
<141> 2000-02-16

<150> US 09/234,208
<151> 1999-01-20

<160> 10

<210> 1
<211> 79
<212> PRT
<213> Homo Sapiens
<220>
<221> Variable
<222> 2
<223> Applicants herein disclose Thr and Ser sequence variants at
this position
<220>
<221> Variable
<222> 5
<223> Applicants herein disclose Leu and Pro sequence variants at
this position
<220>
<221> Variable
<222> 6
<223> Applicants herein disclose Pro and Leu sequence variants at
this position
<220>
<221> Variable
<222> 16
<223> Applicants herein disclose Leu and Gln sequence variants at
this position
<220>
<221> Variable
<222> 18
<223> Applicants herein disclose Met and Leu sequence variants at
this position
<220>
<221> Variable
<222> 21
<223> Applicants herein disclose Gly, Asp, Ala and Val sequence
variants at this position
<220>
<221> Variable
<222> 36

<223> Applicants herein disclose Leu and Ile sequence variants at
this position
<220>
<221> Variable
<222> 54
<223> Applicants herein disclose Pro and Arg sequence variants at
this position
<220>
<221> Variable
<222> 64
<223> Applicants herein disclose Pro and Leu sequence variants at
this position
<220>
<221> Variable
<222> 73
<223> Applicants herein disclose Asp and Asn sequence variants at
this position

<400> 1
Gly Xaa His Ser Xaa Xaa Pro Arg Pro Ala Ala Val Pro Val Pro Xaa
              5   10   15
Arg Xaa Gln Pro Xaa Pro Ala His Pro Val Leu Ser Phe Leu Arg Pro
        20   25   30
Ser Trp Asp Xaa Val Ser Ala Phe Tyr Ser Leu Pro Leu Ala Pro Leu
        35   40   45
Ser Pro Thr Ser Val Xaa Ile Ser Pro Val Ser Val Gly Arg Gly Xaa
    50   55   60
Asp Pro Asp Ala His Val Ala Val Xaa Leu Ser Arg Tyr Glu Gly
65   70   75

<210> 2
<211> 419
<212> PRT
<213> Homo Sapiens
<220>
<221> Variable
<222> 342
<223> Applicants herein disclose Thr and Ser sequence variants at
this position
<220>
<221> Variable
<222> 345
<223> Applicants herein disclose Leu and Pro sequence variants at
this position
<220>
<221> Variable
<222> 346
<223> Applicants herein disclose Pro and Leu sequence variants at
this position
<220>
<221> Variable
<222> 356
<223> Applicants herein disclose Leu and Gln sequence variants at

this position
<220>
<221> Variable
<222> 358
<223> Applicants herein disclose Met and Leu sequence variants at
this position
<220>
<221> Variable
<222> 361
<223> Applicants herein disclose Gly, Asp, Ala and Val sequence
variants at this position
<220>
<221> Variable
<222> 376
<223> Applicants herein disclose Leu and Ile sequence variants at
this position
<220>
<221> Variable
<222> 394
<223> Applicants herein disclose Pro and Arg sequence variants at
this position
<220>
<221> Variable
<222> 404
<223> Applicants herein disclose Pro and Leu sequence variants at
this position
<220>
<221> Variable
<222> 413
<223> Applicants herein disclose Asp and Asn sequence variants at
this position

<400> 2
Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
                  5   10   15
Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Cys Lys
              20   25   30
Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
          35   40   45
Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
      50   55   60
Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val
65   70   75   80
Gln Gly Tyr Val Leu Cys Ala His Asn Gln Val Arg Gln Val Pro Leu
                  85   90   95
Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
              100   105   110
Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Arg Arg Thr Thr Pro
          115   120   125
Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
      130   135   140
Leu Thr Glu Cys Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
145   150   155   160
Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
                                    3

```
                    165                 170                 175
Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
                180                 185                 190
His Pro Cys Ser Pro Cys Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser
            195                 200                 205
Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys
        210                 215                 220
Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys
    225                 230                 235                 240
Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu
                245                 250                 255
His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val
            260                 265                 270
Thr Tyr Asn Thr Asp Thr Phe Glu Ser Cys Pro Asn Pro Glu Gly Arg
        275                 280                 285
Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Lys Leu
    290                 295                 300
Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln
305                 310                 315                 320
Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys
                325                 330                 335
Pro Cys Ala Arg Gly Xaa His Ser Xaa Xaa Pro Arg Pro Ala Ala Val
            340                 345                 350
Pro Val Pro Xaa Arg Xaa Gln Pro Xaa Pro Ala His Pro Val Leu Ser
        355                 360                 365
Phe Leu Arg Pro Ser Trp Asp Xaa Val Ser Ala Phe Tyr Ser Leu Pro
    370                 375                 380
Leu Ala Pro Leu Asp Pro Thr Ser Val Xaa Ile Ser Pro Val Ser Val
385                 390                 395                 400
Gly Arg Gly Xaa Asp Pro Asp Ala His Val Ala Val Xaa Leu Ser Arg
                405                 410                 415
Tyr Glu Gly
```

<210> 3
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> HER-2-specific oligonucleotide primer

<400> 3
tgagcaccat ggagctggc 19

<210> 4
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> HER-2-specific oligonucleotide primer

<400> 4
tccggcagaa atgccaggct cc 22

<210> 5

4

```
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> HER-2 cDNA-specific oligonucleotide primer

<400> 5
aacacagcgg tgtgagaagt gc 22

<210> 6
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> HER-2 ECDIIIa-region-specific oligonucleotide primer

<400> 6
ataccgggac aggtcaacag c 21

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> HER-2 ECDIIIa-region-specific oligonucleotide primer

<400> 7
tctgggtacc cactcactgc 20

<210> 8
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> HER-2 exon-specific oligonucleotide primer

<400> 8
ttcacactgg cacgtccaga cc 22

<210> 9
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> HER-2 cDNA-specific oligonucleotide primer

<400> 9
gcacggatcc atagcagact gaggagg 27

<210> 10
<211> 240
<212> DNA
<213> Homo Sapiens
<220>
```

5

<221> Variable
<222> 62
<223> Applicants disclose C, T, A and G variants at this position

<400> 10
```
ggt wcc cac tca cyg cyc ccg agg cca gct gca gtt cct gtc cct   45
Gly Xaa His Ser Xaa Xaa Pro Arg Pro Ala Ala Val Pro Val Pro
                 5                   10              15

cwg cgc atr cag cct gnc cca gcc cac cct gtc cta tcc ttc ctc   90
Xaa Arg Xaa Gln Pro Xaa Pro Ala His Pro Val Leu Ser Phe Leu
                20                   25              30

aga ccc tct tgg gac mta gtc tct gcc ttc tac tct cta ccc ctg  135
Arg Pro Ser Trp Asp Xaa Val Ser Ala Phe Tyr Ser Leu Pro Leu
                35                   40              45

gcc ccc ctc agc cct aca agt gtc cst ata tcc cct gtc agt gtg  180
Ala Pro Leu Ser Pro Thr Ser Val Xaa Ile Ser Pro Val Ser Val
                50                   55              60

ggg agg ggc cyg gac cct gat gct cat gtg gct gtt sac ctg tcc  225
Gly Arg Gly Xaa Asp Pro Asp Ala His Val Ala Val Xaa Leu Ser
                65                   70              75

cgg tat gaa ggc tga                                          240
Arg Tyr Glu Gly
```